Protagonist: After A Strong Run, Caution Is Advised

About: Protagonist Therapeutics, Inc. (PTGX), Includes: TBPH
by: Early Retiree
This article is exclusive for subscribers.
Early Retiree
Research analyst, value, small-cap, retirement and income

I suggested Protagonist as my best biotech idea in Seeking Alpha's recent biotech roundtable interview.

After returning ~50% over three months, some caution is advised.

Even more so, since the company is clearly nervous about the possibility to lose its most important development partner.

Between the Christmas lows, when my interview was published and yesterday's Q4/18 results, Protagonist (PTGX) had a strong run for a ~50% return. Investors were probably anticipating good news about the PTG-200